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4 A. Agarwal et al. / Journal of Clinical Epidemiology 81 (2017) 3e12AbstractObjectives: Explicit reporting of absolute measures is important to ensure treatment effects are correctly interpreted. We examined the
extent to which authors report absolute effects for patient-important outcomes in abstracts of systematic review (SR).
Study Design and Setting: We searched OVID MEDLINE and Cochrane Database of Systematic Reviews to identify eligible SRs
published in the year 2010. Citations were stratified into Cochrane and non-Cochrane reviews, with repeated random sampling in a 1:1
ratio. Paired reviewers screened articles and recorded abstract characteristics, including reporting of effect measures for the most
patient-important outcomes of benefit and harm.
Results: We included 96 Cochrane and 94 non-Cochrane reviews. About 117 (77.5%) relative measures were reported in abstracts for
outcomes of benefit, whereas only 34 (22.5%) absolute measures were reported. Similarly, for outcomes of harm, 41 (87.2%) relative mea-
sures were provided in abstracts, compared with only 6 (12.8%) absolute measures. Eighteen (9.5%) abstracts reported both absolute and
relative measures for outcomes of benefit, whereas only two (1.1%) abstracts reported both measures for outcomes of harm. Results were
similar between Cochrane and non-Cochrane reviews.
Conclusion: SR abstracts seldom report measures of absolute effect. Journal editors should insist that authors report both relative and
absolute effects for patient-important outcomes.  2016 Elsevier Inc. All rights reserved.
Keywords: Absolute measures; Patient-important outcomes; Explicit reporting; Abstract reporting; Cochrane reviews; Non-Cochrane reviews1. Introduction
Readers of the medical literature often first refer the ab-
stract of a systematic review (SR) to judge the magnitude of
results, including the point estimates for benefit and harm
and their associated confidence intervals [1], and may,
because of limited access to full-text journals and time con-
straints, rely solely on abstracts. The Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRIS-
MA) reporting guidelines for abstracts recommend that re-
sults for the main outcomes of both benefits and harms
should be reported as part of the synthesis of the results,
preferably providing the number of studies and participants
for each included outcome, summary measures (estimates),
and corresponding measure of precision [2]. The guidelines
encourage the inclusion of information on the direction and
size of effect in both absolute and relative measures [2].
Including measures of absolute effects is particularly
important for clinical decision making. Expressing treat-
ment effects in relative terms yields apparently larger treat-
ment effects than if absolute terms are used (e.g., a 50%
relative risk reduction can mean an absolute risk reduction
[ARR] of 1%; i.e., 2e1%), and this difference influences
the judgment of clinicians and patients regarding the treat-
ment options [3]. Relative measures may also exaggerate
small between-group differences for uncommon events
and minimize large differences for common events. Thus,
exclusively presenting measures of relative effect without
absolute measures can be misleading and present further
challenges to patients and clinicians attempting to trade
off between desirable and undesirable effects [4e7]. Recent
guidelines by the Cochrane Collaboration have also recom-
mended that review authors report estimates of absolute ef-
fects in their study abstracts and acknowledged that they
are more easily interpretable than relative effects [8].Although there is a high concordance between abstract
and full-text article reporting of single primary outcomes
in randomized controlled trials (RCTs) published in top
medical journals, little is known about the extent to which
abstracts of SRs report the most patient-important out-
comes of benefit and harm and the extent to which abstracts
report absolute measures of effect [9]. Considering that
health care professionals often rely on study abstracts for
decision making, we examined the extent to which authors
reported absolute effects on patient-important outcomes in
the abstracts of Cochrane and non-Cochrane reviews re-
porting dichotomous outcomes.2. Methods
2.1. Objectives
1. To examine the extent to which the most patient-
important outcomes are reported in the full texts
and abstracts of Cochrane and non-Cochrane reviews.
2. As judged from abstracts alone, to examine the use of
explicit reporting of patient-important outcomes.
3. As judged from abstracts alone, to examine the extent
to which absolute effects are reported for patient-
important outcomes.
4. To examine the extent to which the most patient-
important outcomes are reported in the full texts
and plain language summaries of Cochrane reviews.2.2. Search strategy
Based on a publically available study protocol [10],
which we modified to include a focus on abstract reporting
5linical Epidemiology 81 (2017) 3e12What is new?
Key findings
 Authors frequently do not report the most patient-
important outcomes of benefit and harm in system-
atic review (SR) abstracts.
 Authors seldom report absolute measures of effect
for outcomes of benefit or harm in SR abstracts.
What this adds to what was known?
 Although there is a high concordance between ab-
stract and full-text article reporting of single pri-
mary outcomes in randomized trials published in
top medical journals, little is known about the
extent to which abstracts of SRs report the most
patient-important outcomes of benefit and harm
and the extent to which abstracts report absolute
measures of effect.
What is the implication and what should change
now?
 To facilitate health care decision making, journal
editors should insist that authors report the most
patient-important outcomes of benefit and harm
in abstracts using absolute measures of effect.
 Two or more representative absolute effects should
be presented if baseline risks vary substantially.
A. Agarwal et al. / Journal of Cof patient-important outcomes, we searched OVID MED-
LINE and the Cochrane Database of Systematic Reviews
to identify eligible SRs published in the year 2010. An
adapted version of the SR filter designed by the McMaster
University Health Information Research Unit was used to
retrieve non-Cochrane SRs and Cochrane SRs using the
search by journal option. Citations were exported into Dis-
tillerSR (Evidence Partners, Ottawa, Ontario, Canada).
2.3. Study selection and data extraction
A sample of 2,328 studies was identified by our search.
After the removal of duplicates, 2,278 studies were strati-
fied into two groups: Cochrane and non-Cochrane reviews.
Within each stratum, repeated random sampling in a 1:1 ra-
tio was used in an iterative process, where pairs of re-
viewers independently screened studies at the title and
abstract and full-text levels from both strata. A sample size
of 202 SRs was obtained, of which 12 SRs were further
deemed ineligible, leaving 190 eligible SRs. We included
studies described as SR or meta-analysis that were pub-
lished in English; reported a search strategy in at least
one database; included a comparison of at least two inter-
ventions in humans; reported at least one dichotomousoutcome; included at least one RCT; and included only
RCTs as primary studies. SRs that only included primary
outcomes of harm with no patient-important outcomes of
benefit were excluded.
Among eligible SRs, pairs of reviewers selected and ex-
tracted data on the population, intervention(s), compara-
tor(s), and the most patient-important outcomes of benefit
and harm. Each team of extractors consisted of one more
experienced reviewer and one less experienced reviewer.
Pretested and standardized forms with extensive instruc-
tions were used for eligibility screening, outcome selection,
and data abstraction, and any discrepant judgments between
reviewers were resolved by consensus, or, if necessary, by a
third reviewer. Each reviewer team completed calibration
exercises before all screening and abstraction phases to
further ensure reliability.
The relative patient importance of outcomes was
guided by a hierarchy (Table 1). Mortality (category I),
morbidity (category II), and symptoms/quality of life/
functional status (category III) were considered patient-
important outcomes, whereas surrogate outcomes (cate-
gory IV) were not. Categories I and II were considered
critically important, whereas category III was considered
important.
If outcomes of harm or benefit reported by a trial were
equally important, the outcome with the largest number
of observations was chosen. For composite outcomes, the
component of greatest patient importance was selected.
When the necessary disaggregated data for a composite
outcome of interest was unavailable, we chose the next
outcome of greatest patient importance that was reported.
Data abstractors documented the reporting of absolute
and relative treatment measures of effect for all eligible re-
view abstracts and if authors used explicit or implicit state-
ments when reporting the most patient-important outcome
of benefit and harm. We defined explicit reporting as a
direct statement for a specific outcome with an absolute
or relative numerical measure. For example, the following
statement would be considered explicit reporting: ‘‘In the
five studies, 143 people allocated to calcium had a myocar-
dial infarction compared with 111 allocated to placebo
(hazard ratio 1.31, 95% confidence interval 1.02 to 1.67,
P 5 0.035).’’ We defined implicit reporting as either a
broad or an indirect reference to the specific outcome or
lacking an absolute or relative numeric measure. For
example, the following statement would be considered im-
plicit reporting: ‘‘In the five studies, serious harms were
associated with calcium compared to placebo’’. As a sec-
ondary outcome, we documented the proportion of ab-
stracts and Cochrane plain language summaries that
reported the beneficial and harmful outcomes judged as
most patient-important outcome from the full text.
Absolute measures of interest included the ARR or risk
difference (RD), number needed to treat (NNT), and the pro-
portion of beneficial or harmful events per group. Relative
measures of interest included relative risk or rate ratio
Table 1. Hierarchical approach to prioritization of patient-important outcomes
Category Description Examples Critically important or important
I Mortality  All-cause mortality
 Disease-specific mortality
Critically important
II Morbidity  Cardiovascular major morbid events
 Other major morbid events (e.g., loss of vision, seizures,
fracture, revascularization)
 Recurrence/relapse/remission of cancer/disease-free survival
 Renal failure requiring dialysis
 Hospitalizations
 Infections (e.g., pneumonia, gastroenteritis)
 Dermatologic (e.g., skin necrosis, StevenseJohnson syndrome,
and toxic epidermal necrolysis)
 Rheumatologic disorders such as exacerbation of a
rheumatologic disease (e.g., Behcet disease,
rheumatoid arthritis)
Critically important
III Symptoms/quality of life/functional
status









 Postoperative atrial fibrillation
 Cognitive function
Somewhat important
Abbreviations: TB, tuberculosis; FEV1, forced expiratory volume in the first second.
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some included studies reported both absolute and relative
measures in their abstracts, it was noted that the number
of measures reported exceeded the number of included
studies.
2.4. Data analysis
Frequencies and proportions, and the associated mea-
sures of statistical dispersion (interquartile range [IQR]),
were calculated for all items, stratified by Cochrane and
non-Cochrane SRs. We compared proportions between Co-
chrane and non-Cochrane SRs with the chi-square test.
We calculated the chance-corrected agreement between
reviewers regarding whether an absolute effect estimate
was reported for the outcome of interest and interpreted
the results according to guidelines proposed by Landis
and Koch [11]. Agreement of 0.01e0.20 was considered
as slight, 0.21e0.40 as fair, 0.41e0.60 as moderate,
0.61e0.80 as substantial, and 0.81e1.00 as very good.
All data analyses were performed using SPSS statistical
software, version 18.0 (SPSS, Inc., Chicago, IL, USA).3. Results
We identified 2,278 potentially eligible articles after
removal of duplicates. After stratification between Cochrane
and non-Cochrane SRs, repeated random sampling in a 1:1 ra-
tio and initial title and abstract screening, 487 articles were
deemed eligible for full-text review, of which 202 proved
eligible. Twelve SRs were subsequently excluded, having onlyreported a harm-related outcome without an eligible outcome
of benefit or because of study design, leaving 190 eligible SRs
(96 Cochrane and 94 non-Cochrane SRs) (Fig. 1).
The 190 eligible reviews included a median of five RCTs
(IQR, 2e9), median number of 851 patients (IQR,
225e2,108), and median of 111.5 events for the outcome
of interest (IQR, 31.5e391). Of the 190 reviews, 141
(74.2%) included a focus on a medical area and 55
(29.0%) on a surgical area, with six (3.2%) studies including
a focus on both areas. The primary outcome represented a
benefit in 172 (90.5%) of the reviews and harm in the remain-
ing 18 (9.5%). In 135 (71.1%) of eligible SRs, the primary
outcome chosen by the SR investigators was considered pa-
tient important (Tables 2 and 3).3.1. Reporting of outcomes of benefit in the abstract
Of 190 SRs, 144 (75.8%) reported the outcome of benefit
we judged most patient important from the full text in the ab-
stract. Five (2.6%) reported only a composite outcome in the
abstract despite reporting disaggregated data in their full text.
Thirty-one (16.3%) SRs did not report any of the outcomes
of benefit in their abstract. Results were similar between Co-
chrane and non-Cochrane SRs (P 5 0.91) (Table 4).
As judged from abstract reporting alone, 161 (84.7%) ab-
stracts reported a patient-important outcome of benefit. Of
these, 121 (75.2%) abstracts provided an explicit statement,
and 40 (24.8%) provided an implicit statement. Twenty-nine
SRs (15.3%) did not report an important outcome of benefit
in their abstract. No significant differences were observed
between Cochrane and non-Cochrane SRs (Table 4).
Fig. 1. Flow diagram of the literature screening process. RCTS, randomized controlled trials.
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of 151 absolute and/or relative measures in their abstracts,
of which 117 (77.5%) were relative measures and 34
(22.5%) were absolute measures. Eighteen (9.5%) abstracts
provided both relative and absolute measures, with ARR/
RD combined with RR (n 5 4) and rate of events per group
combined with RR (n 5 6) being the most common combi-
nations reported. No significant differences were observed
between Cochrane and non-Cochrane SRs (Table 4).3.2. Reporting of outcomes of harm in the abstract
Of 190 SRs, 73 (38.4%) reported critically important
outcomes of harm in the full text. Of these, 46 (63.0%) re-
ported this outcome in the abstract. Of our 190 SRs, 97(51.1%) reported important outcomes of harm in the full
text. Of these, 67 (69.1%) reported this outcome in the ab-
stract. No significant differences were observed between
Cochrane and non-Cochrane SRs for critically important
or important outcomes of harm (P 5 0.13) (Table 5).
As judged from abstract reporting alone, 87 (45.8%) ab-
stracts reported a patient-important outcome of harm. Of
those, an explicit statement was provided in 36 (41.4%)
SRs, whereas an implicit statement was provided in 51
(58.6%) SRs. No significant differences were observed be-
tween Cochrane and non-Cochrane SRs (Table 5).
Forty-two (22.1%) SRs reported a total of 47 absolute
and/or relative measures in their abstracts, of which 41
(87.2%) were relative measures and only 6 (12.8%) were ab-
solute measures. Only two (1.1%) abstracts provided both a
Table 2. General characteristics of the included systematic reviews
Characteristics of reviews
Cochrane Non-Cochrane Overall
Pn [ 96 (%) n [ 94 (%) n [ 190 (%)
Type of analysis developed by authorsa
Standard meta-analysis 86 (89.6) 90 (95.7) 176 (92.6) 0.16
Metaregression 3 (3.1) 13 (13.8) 16 (8.4) 0.009
Individual patient data meta-analysis 2 (2.1) 4 (4.3) 6 (3.2) 0.44
Network meta-analysis or multiple treatment comparison 1 (1) 0 (0) 1 (0.5) 1
No statistical pooling conducted 6 (6.3) 2 (2.1) 8 (4.2) 0.28
Characteristics of meta-analysis
Median number of trials included (IQR) 3 (2e8) 7 (4e9) 5 (2e9) !0.0001
Median number of patients included (IQR) 567 (173e1,345) 1,402 (484e3,517) 851 (225e2,108) 0.003
Median number of events included (IQR) 59 (16e185) 316 (72e886) 111.5 (31.5e391) !0.0001
Characteristics of meta-analysisa
Medical area 63 (65.6) 78 (83.0) 141 (74.2) 0.006
Surgical area 36 (37.5) 19 (20.2) 55 (29.0) 0.009
Intervention for comparison of interest
Pharmacologic 68 (70.8) 53 (56.4) 121 (63.7) 0.04
Nonpharmacologic 28 (29.2) 41 (43.6) 69 (36.3)
Control for comparison of interest
Pharmacologic 35 (36.4) 28 (29.8) 63 (33.2) 0.61
Nonpharmacologic 33 (34.4) 37 (39.4) 70 (36.8)
Placebo 28 (29.2) 29 (30.8) 57 (30.0)
Use of GRADE
Yes 27 (28.1) 3 (3.2) 30 (15.8) !0.0001
No 68 (70.8) 90 (95.7) 158 (83.1)
Unclear 1 (1.1) 1 (1.1) 2 (1.1)
Evaluation of risk of bias
Risk of bias tool 82 (85.4) 9 (9.6) 91 (47.9) !0.0001
By dimensions 8 (8.3) 29 (30.9) 37 (19.5)
Jadad or other scales 4 (4.2) 29 (30.9) 33 (17.4)
Not evaluated 0 (0.0) 16 (17.0) 16 (8.4)
Other 2 (2.1) 11 (11.6) 13 (6.8)
Funding
For profit 2 (2.1) 4 (4.3) 6 (3.2) 0.44
Not for profit 62 (64.6) 33 (35.1) 95 (50) !0.0001
Not funded 10 (10.4) 11 (11.7) 21 (11.1) 0.78
Not reported 23 (24) 47 (50) 70 (36.8) 0.0002
Did authors report ties to industry?
Yes 20 (20.8) 15 (16) 35 (18.4) 0.0002
No 57 (59.4) 34 (36.2) 91 (47.9)
Not reported 19 (19.8) 43 (45.7) 62 (32.6)
Unclear 0 (0) 2 (2.1) 2 (1.1)
Mean quality score on the AMSTAR instrument (SD) 10 (9e10) 7 (6e8) 9 (7e10) !0.0001
Abbreviations: IQR, interquartile range; GRADE, Grades of Recommendation, Assessment, Development and Evaluation; AMSTAR, A Measure-
ment Tool to Assess Systematic Reviews; SD, standard deviation.
Statistically significant P-values are indicated in bold.
a The questions allow multiple selection; therefore, sum of percentages might exceed 100%.
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sure (ARR/RD). No significant differences were observed
between Cochrane and non-Cochrane SRs (Table 5).
3.3. Reporting of outcomes of benefit and harm in
Cochrane plain language summaries
Among 94 (97.9%) Cochrane SRs reporting a patient-
important outcome of benefit in their full text, 43 (45.7%)
explicitly reported the most patient-important outcome of
benefit from the full text in their plain language summary,
28 (29.8%) reported the outcome as an implicit statement,
and 23 (24.5%) did not report the outcome in the summary
(Table 6).Among 68 (70.8%) Cochrane SRs reporting a patient-
important outcomeofharm in their full text, 20 (29.4%)explic-
itly reported themost patient-important outcome of harm from
the full text in their plain language summary, 17 (25.0%) re-
ported the outcome as an implicit statement, and 31 (45.6%)
did not report the outcome in the summary (Table 6).4. Discussion
4.1. Principal findings
Among 190 eligible SRs (96 Cochrane and 94 non-
Cochrane) reporting dichotomous outcomes, we found that
Table 3. Patient-important outcomes in the included systematic reviews
Characteristics of reviews
Cochrane Non-Cochrane Overall
Pn [ 96 (%) n [ 94 (%) n [ 190 (%)
Is the most patient-important outcome the primary outcome for the authors?
Yes 64 (66.7) 45 (47.9) 109 (57.4) !0.0001
No, but some other outcome specified as primary 21 (21.9) 12 (12.8) 33 (17.4)
Authors did not specify a primary outcome 11 (11.5) 37 (39.3) 48 (25.3)
Is the primary outcome of the authors patient important?
Yes 81 (84.4) 54 (57.5) 135 (71.1) !0.0001
No 6 (6.3) 5 (5.3) 11 (5.8)
Authors did not specify a primary outcome 9 (9.5) 35 (36.8) 44 (23.2)
Most patient-important outcome one of benefit or harm?
Beneficial outcome 85 (88.5) 87 (92.6) 172 (90.5) 0.35
Harm outcome 11 (11.6) 7 (7.4) 18 (9.5)
Relative effect estimates for the most patient-important outcome
Relative risk 58 (60.4) 53 (56.4) 111 (58.4) 0.57
Odds ratio 24 (25) 28 (29.8) 52 (27.4) 0.46
Hazard ratio 8 (8.3) 3 (3.2) 11 (5.8) 0.21
RRR 0 (0) 1 (1.1) 1 (0.5) 1
Rate ratio 1 (1) 1 (1.1) 2 (1.1) 1
Other 5 (5.2) 9 (9.6) 14 (7.4) 0.25
Abbreviation: RRR, relative risk reduction.
Statistically significant P-values are indicated in bold.
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outcomes of benefit and harm in their abstracts and plain
language summaries. Authors seldom reported absolute
measures of effect for either beneficial outcomes or harmful
outcomes. These findings proved similar in Cochrane and
non-Cochrane SRs.4.2. Previous findings
The findings of our study are consistent with a structured
review of general medical and public health journals that
examined the frequency of absolute and relative measure re-
porting in health inequalities research [12]. Evaluating 344
articles published in 2009 among the top four generalTable 4. Reporting of patient-important outcomes of benefit
Variable of interest
Reporting of the patient-important outcome of benefit judged most importan
Most important outcome in the full text is also reported in the abstract
Disaggregated data reported in the full text, but only a composite reported
Reported in the full text but not in the abstract
Article has no patient-important outcomes reported in the full text
Explicit vs. implicit reporting of the outcome of benefit in the abstract
Explicit reporting: direct statement, with numerical value provided
Implicit reporting: direct statement, with no numerical value provided
Implicit reporting: indirect statement, with numerical value provided
Implicit reporting: indirect statement, with no numerical value provided
No patient-important beneficial outcomes reported in the abstract
Absolute vs. relative reporting of the outcome of benefit in the abstract
Relative measure provided in the abstract (RR, OR, HR, RRR, or rate rat
Absolute measure provided in the abstract (ARR/RD, NNT/NNTB, NNH/N
events per group, or rate difference)
No patient-important beneficial outcomes reported in the abstract
No numerical value provided
Abbreviations: RR, relative risk; OR, odds ratio; HR, hazard ratio; RRR, re
NNT, number needed to treat; NNTB, number needed to treat (benefit); NNmedicine and top four public health journals, the review
found that only 138 reported numeric data in the abstract;
among these, 88% reported a relative measure of effect,
9% reported only an absolute measure, and 2% reported both
[12]. Similarly, an evaluation of 182 SR abstracts published
in 2009, Beller et al. [9] found that only 137 reported
numeric data in the abstract; among these, 45 (25%) did
not report an absolute measure or a relative measure, and
87 (48%) reported only relative measures. In contrast, 28
(15%) abstracts reported only absolute measures, 14 (8%)
reported data allowing both absolute and relative measures
to be calculated, and only 8 (4%) reported both measures [9].
Our study builds on the findings of these two studies but
focuses on patient-important outcome reporting inCochrane Non-Cochrane Overall P
t in the abstract n 5 96 (%) n 5 94 (%) n 5 190 (%)
73 (76.0) 71 (75.5) 144 (75.8) 0.91
in the abstract 3 (3.1) 2 (2.1) 5 (2.6)
16 (16.7) 15 (16.0) 31 (16.3)
4 (4.2) 6 (6.4) 10 (5.3)
n 5 96 (%) n 5 94 (%) n 5 190 (%)
63 (65.6) 58 (61.7) 121 (63.7) 0.76
13 (13.5) 10 (10.6) 23 (12.1) 0.50
1 (1.0) 5 (5.3) 6 (3.2) 0.21
8 (8.3) 3 (3.2) 11 (5.8) 0.21
11 (11.5) 18 (19.2) 29 (15.3) 0.23
n 5 96 (%) n 5 94 (%) n 5 190 (%)
io) 57 (53.3) 60 (56.1) 117 (54.7) 0.38
NTH, rate of 18 (16.8) 16 (15.0) 34 (15.9) 0.82
11 (10.3) 18 (16.8) 29 (13.6) 0.23
21 (19.6) 13 (12.1) 34 (15.9) 0.13
lative risk reduction; ARR, absolute risk reduction; RD, risk difference;
H, number needed to harm; NNTH, number needed to treat (harm).
Table 5. Reporting of patient-important outcomes of harm
Variable of interest Cochrane Non-Cochrane Overall P
Patient ‘‘critically important’’ outcome of harm reporting in the abstract n 5 96 (%) n 5 94 (%) n 5 190 (%)
‘‘Critically important’’ outcomes of harm are explicitly reported in the abstract 18 (18.8) 15 (16.0) 33 (17.4) 0.13
‘‘Critically important’’ outcomes of harm are implicitly reported in the abstract 8 (8.3) 5 (5.3) 13 (6.8)
‘‘Critically important’’ outcomes of harm are not reported in the abstract 18 (18.8) 9 (9.6) 27 (14.2)
No ‘‘critically important’’ outcomes of harm are reported in the full text 52 (54.2) 65 (69.1) 117 (61.6)
Patient-important outcome of harm reporting in the abstract n 5 96 (%) n 5 94 (%) n 5 190 (%)
‘‘Important’’ outcomes of harm are explicitly reported in the abstract 25 (26.0) 15 (16.0) 40 (21.1) 0.09
‘‘Important’’ outcomes of harm are implicitly reported in the abstract 14 (14.6) 13 (13.8) 27 (14.2)
‘‘Important’’ outcomes of harm are not reported in the abstract 19 (19.8) 11 (11.7) 30 (15.8)
No ‘‘important’’ outcomes of harm are reported in the full text 38 (39.6) 55 (58.5) 93 (48.9)
Explicit vs. implicit reporting of the most patient-important outcome of harm in the abstract n 5 96 (%) n 5 94 (%) n 5 190 (%)
Explicit reporting: direct statement, with numerical value provided 18 (18.8) 18 (19.1) 36 (18.9) 1
Implicit reporting: direct statement, with no numerical value provided 14 (14.6) 10 (10.6) 24 (12.6) 0.38
Implicit reporting: indirect statement, with numerical value provided 2 (2.1) 4 (4.3) 6 (3.2) 0.68
Implicit reporting: indirect statement, with no numerical value provided 15 (15.6) 6 (6.4) 21 (11.1) 0.04
No important or critically important harmful events reported in the abstract 47 (49.0) 56 (59.6) 103 (54.2) 0.11
Absolute vs. relative reporting of the most patient-important outcome of harm in the abstract n 5 96 (%) n 5 94 (%) n 5 190 (%)
Relative measure provided in abstract (RR, OR, HR, RRR, or rate ratio) 21 (20.8) 20 (21.3) 41 (21.0) 0.72
Absolute measure provided in the abstract (ARR/RD, NNT/NNTB, NNH/NNTH, rate of
events per group, or rate difference)
4 (4.0) 2 (2.1) 6 (3.1) 0.62
No important or critically important harmful events reported in the abstract 47 (46.5) 56 (59.6) 103 (52.8) 0.11
No numerical value reported in the abstract 29 (28.7) 16 (17.0) 45 (23.1) 0.04
Abbreviations: RR, relative risk; OR, odds ratio; HR, hazard ratio; RRR, relative risk reduction; ARR, absolute risk reduction; RD, risk difference;
NNT, number needed to treat; NNTB, number needed to treat (benefit); NNH, number needed to harm; NNTH, number needed to treat (harm).
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all medical and surgical fields. In line with their findings,
we also found an overreliance on relative vs. absolute mea-
sures in SR abstracts, and only a small number of SR ab-
stracts that reported both types of measures.4.3. Strengths and limitations
Our study has several strengths. We established explicit
eligibility criteria, conducted sensitive searches to identify
relevant data, and conducted eligibility screening and data
abstraction independently and in duplicate with discussion
to resolve discrepancies and establish consensus. We choseTable 6. Reporting of most patient-important outcomes in Cochrane
plain language summaries
Variable of interest n [ 96 (%)
Most patient-important outcome of benefit reporting in
the plain language summary
Yes, reported as explicit statement 43 (44.8)
Yes, reported as implicit statement 28 (29.2)
Patient-important outcomes reported in the full text
but not in the plain language summary
23 (24.0)
Article has no patient-important outcomes reported in
the full text
2 (2.1)
Most patient-important outcome of harm reporting in
the plain language summary
Yes, reported as an explicit statement 20 (20.8)
Yes, reported as an implicit statement 17 (17.7)
Patient-important harmful event reported in the full
text but not in the plain language summary
31 (32.3)
Article has no patient-important harmful event
reported in the full text
28 (29.2)a large and representative sample of both Cochrane and
non-Cochrane SRs, making the findings of our study broadly
applicable. Unlike previous studies in the area [12], our find-
ings are not restricted to SRs from top journals. We assessed
the reporting and presentation format of patient-important
outcomes in abstracts, evaluating the use of absolute and
relative measures and explicit and implicit statements, issues
that have not been previously studied.
Our study has several limitations. First, there was
considerable judgment involved in many of the data-
abstracting decisions, in particular the judgment of out-
comes of most importance. We did, however, provide
extensive instructions and conducted calibration exercises.
Second, our search was limited to MEDLINE and the
Cochrane Database of Systematic Reviews, which might
limit the generalizability of our findings. It is, however,
likely that noneMEDLINE-indexed journals do no better
than the MEDLINE-indexed journals we sampled.
Third, it may be that the quality of reporting has
improved in recent years as a result of guidance from Grades
of Recommendation, Assessment, Development and Evalua-
tion (GRADE) and the Methodological Expectations of Co-
chrane Intervention Reviews project, which encourage
reporting of effect estimates in both relative and absolute ef-
fects. Furthermore, the increased uptake of GRADE method-
ology and associated Summary of Findings table in SRs,
particularly Cochrane SRs, is likely to have increased the
use of absolute measures in SRs, and by extension, in their
abstracts.
A 2012 study involving a cohort of Cochrane SRs
showed that 45% of the SRs used the GRADE approach
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ly 6% of non-Cochrane SRs [13]. Considering the inclusion
of GRADE as a surrogate of absolute estimates in the SR,
we may estimate an approximate increase of 6% in absolute
measure reporting in the SR over 2 years since our 2012
data. Given that it is very unlikely that non-Cochrane SRs
have shown greater improvement than Cochrane SRs in
the interval, it is unlikely that our study markedly underes-
timates reporting of absolute measures in the abstract.4.4. Implications and future directions
Authors should, however, be careful in communicating the
size of treatment effects. Assuming results, in relative terms,
are significant: to calculate RDs, authors should ideally apply
the relative estimate (e.g., RR) to the baseline risk from well-
designed, large, and observational studies. If such observa-
tional studies are not available, authors should consider the
variation in the baseline risk among included studies in the
SR. If there is little baseline variation, authors can use the me-
dian control group risk from the included studies. If large
variation exists, authors can consider using two or more
representative baseline risks from the included studies [14].
For example, a meta-analysis of probiotics for the preven-
tion of Clostridium difficile infection included 21 RCTs, esti-
mated an RR of 0.39, and observed baseline risks ranging
from 0% to 40%, with a mean risk in control groups of
3.8% [15,16]. Using the mean baseline risk of 3.8%, the
RR of 0.39 corresponds to an ARR of 2.3% and an NNT
of 43. Using the same RR of 0.39, based on the control
group of the largest RCT to date (n 5 1,488), the baseline
risk of 1.2% corresponds to an ARR of 0.73% and an
NNT of 137 [17]. In a second example drawn from an actual
abstract: ‘‘patients randomized to primary percutaneous cor-
onary intervention (PPCI) had lower mortality than did pa-
tients randomized to fibrinolysis (5.3% vs 7.9%, adjusted
odds ratio 0.63, 95% CI 0.42-0.84, P ! 0.001). The interac-
tion between risk score and allocated treatment interaction
term had no significant contribution (P5 0.52) to the model,
indicating that the relative mortality reduction by PPCI was
similar at all levels of estimated risk. In contrast, the absolute
risk reduction was strongly related to estimated risk at base-
line: the numbers needed to treat to prevent a death by PPCI
vs. fibrinolysis was 516 in the lowest quartile of estimated
risk compared with only 17 in the highest quartile’’ [18].
As illustrated previously, the absolute size of the treatment
effect can vary substantially depending on the baseline risk.
In cases like the two described, reporting only the pooled
mean ARR can be as uninformative or misleading as not re-
porting ARR at all, indicating that the assessment of the
baseline risk in clinical decision making is crucial [19,20].
Our findings suggest that major improvements in the re-
porting of absolute measures for patient-important outcomes
in Cochrane and non-Cochrane SR abstracts are necessary.
The PRISMA consensus statement on recommended items
to include in the reporting of SRs and meta-analyses aimsto promote transparency and complete reporting [21]. In
its elaboration document, PRISMA encourages authors to
report main results in the data synthesis section of their ab-
stract, using numerical results with confidence intervals for
the SRs’ most important outcomes, and ideally, with specifi-
cations of the number of studies and participants included in
the analyses [22]. This is reaffirmed in the PRISMA for ab-
stracts checklist published in 2013 [2], which suggests that
in addition to presenting the baseline risk, the presentation
of results for the main outcomes of benefit and harm should
include the number of studies and participants, summary
measures, confidence intervals, direction of effect and size
of effect (e.g., lower, fewer, reduced; and greater, more,
increased). With respect to absolute measures of effect, the
PRISMA statement provides guidance (although somewhat
limited): when a percentage is used, the baseline risk should
also be shown, which allows the reader to see what the ab-
solute benefit or harm is, and calculate whichever measures
they choose. The guideline also suggests that results be pre-
sented in terms meaningful to clinicians and patients,
including kilograms, days, and percentages [2].
PRISMA for abstracts neither, however, does provide
guidance to authors regarding the inclusion of the most
patient-important outcomes of benefit and harm nor does
it emphasize the need to report absolute measures of effect.
The low proportions of SRs reporting patient-important
outcomes and absolute measures are perhaps unsurprising
in the light of the guidance provided to authors of SRs.5. Conclusions
Strong and explicit guidance in authoritative reporting
guidelines, such as those provided as part of the PRISMA
abstract statement, should better address patient-important
outcome reporting with absolute measures of effect. To
facilitate health care decision making, journal editors
should insist, in abstracts, that authors report all prespeci-
fied outcomes, which should include the most patient-
important outcomes of benefit and harm in abstracts using
absolute measures of effect. When interpreting research re-
sults based on abstract reporting, users of SRs should be
aware of the merit of absolute effects for decision making.Acknowledgments
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